Summary. Factor XI (FXI)-deficient patients may develop excessive bleeding after trauma or surgery. Replacement therapy should be considered in high-risk situations, especially when FXI levels are below 20 IU dL
Introduction
Factor XI (FXI) deficiency is a rare autosomal coagulation disorder with an estimated prevalence of 1 in 1 000 000 individuals [1] . It is the second most commonly reported rare bleeding disorder according to the current global survey of the World Federation of Haemophilia [2] . This disorder is observed in many parts of the world and the incidence of severe form is very population dependent. Unlike haemophilia, the clinical manifestations of this disorder are generally mild [1, 3, 4] . Most severely FXI-deficient patients (FXI activity below 20 IU dL À1 ) are at a higher risk of bleeding, but some patients shows no manifestations. On the other hand, some individuals with partial deficiency may develop haemorrhagic symptoms after injury or surgery. The bleeding history, the associated haemorrhagic (or prothrombotic) risk factors and the severity of the scheduled procedure must be considered when evaluating the need for FXI correction [4, 5] . For many years, fresh frozen plasma (FFP) was the only replacement treatment. However, since FXI levels in FFP are low and variable, large amounts of plasma are often required which may lead to volume overload [6, 7] . In addition, FFP may carry the risk of allergic reactions and the potential for exposure to blood-borne infectious agents. Therapeutic infusions of FXI concentrate are commonly used in some countries. Two human plasma-derived FXI concentrates are currently available: one with a marketing authorization since 1998 held by LFB Biomedicaments, LesUlis, France (HEMOLEVEN), and the other manufactured by BioProducts Laboratory, Elstree, UK and delivered under compassionate use. A postmarketing study was conducted in France on patients treated with HEMOLEVEN to document treatment practices.
Patients and methods

Study population
This study was a prospective, multicentre, observational, non-interventional study conducted from November 2006 to November 2009. Patients with inherited FXI deficiency of any gender, age or disease severity, previously treated or untreated with FFP or a FXI concentrate were eligible if replacement therapy was planned. The investigator reported the bleeding history and exact cumulative exposure days to FXI replacement (concentrate and/or FFP) as well as any inhibitor observed. Clinical and biological follow-up was conducted according to the routine procedures in each centre. The same patient could experience more than one therapeutic situation. The detailed daily replacement therapy and laboratory parameters as well as concomitant medications (i.e. antifibrinolytic drugs used at any time, heparin or other thrombo-prophylactic agents) were recorded.
Treatment
HEMOLEVEN is a highly purified human coagulation FXI (100 U mL
À1
) prepared in France from donor plasma since 1992. Several reports on its use have been published [8] [9] [10] . The concentrate is manufactured using a filter adsorption step followed by chromatography on a cation-exchange resin [11] . Virus elimination/inactivation relies on a combination of solvent/detergent and nanofiltration (15 nm filter) procedures [12] . Human antithrombin (4 IU mL À1 ), sodium heparin (4.5 IU mL
) and C1 esterase inhibitor (2.6 U mL
) are added as stabilizers and to protect against in vitro FXI activation during manufacturing. The dosage was determined by the treating physician based on the Summary of Product Characteristics (SmPC) that recommends therapeutic FXI levels of approximately 30-40% (0.3-0.4 IU mL À1 of plasma).
Normal recovery is estimated at 2 U dL À1 per U kg À1 [9] ; thus, for severe deficiency patients, this corresponds to a dose of about 15 U kg
. For lower recovery, the dose should not exceed 30 U kg À1 to prevent the risk of thrombosis [13, 14] . In addition, injections more often than every 48 h are not necessary due to the long FXI half-life of 45.5 AE 7.9 h in plasma [9] .
Efficacy assessment
The investigators rated the efficacy of HEMOLEVEN for overt bleeding or for prophylaxis in surgery, childbirth or invasive procedures as excellent (haemostasis similar to that expected for normal individuals), good (slightly excessive bleeding at the surgical incision), moderate (moderately excessive bleeding) or none (severe uncontrolled bleeding).
FXI:C incremental recovery (IR) was calculated based on the preinfusion plasma levels and the 0.5-h postinfusion level, in the absence of bleeding and not during pregnancy, as follows:
Factor XI dose (U)
Safety assessment
Safety was evaluated based on adverse events (AEs) suspected to be related to the study drug or not, occurring within 10 days of administration and corresponding to about five half-lives of the protein. In addition, all serious AEs (SAEs), regardless of their relationship with the study drug, were also reported. Death or life-threatening complications, congenital abnormality in the new-born, permanent or transient significant disability, hospitalization or prolongation of hospitalization, medically significant AEs (including inhibitor development) considered as SAEs. The investigator rated the relationship with the study product as "not related", "doubtful", "possible" or "probable". Both the monitoring schedule and the frequency of inhibitor testing were determined by the treating physician. All these tests were performed by the local laboratories at each participating centre.
Statistical analysis
The results were analysed descriptively. Quantitative variables were expressed in terms of mean AE standard deviation (SD), median, minimum and maximum. Qualitative variables were summarized using frequency tables. The percentage of responses judged to be either excellent or good was presented. Where useful, the confidence interval (CI) using the exact method and the P-value (P; considered significant when <0.05) were provided.
Ethics
This study was approved by the French Advisory Committee for the Treatment of Data for Health Research (CCTIRS) and the French Data Protection Committee (CNIL). This work was conducted in accordance with Good Clinical Practice Guidelines (ICH E6) with strictly controlled data collection procedures. Written informed consent was obtained from each participating patient.
Results
Population characteristics and HEMOLEVEN use
Our study enrolled a total of 44 patients. The baseline characteristics of the study population are shown in ) was used because the full content of vial was infused, or the exact content of the vial was unidentified. The concomitant treatments during surgery included 40 mg per day enoxaparin in 10 procedures (23.3%) and tranexamic acid in 11 procedures either in association with FXI (eight procedures, 18.6%) or later (three procedures, 7.0%).
The surgeries and treatments in 31 patients with basal FXI levels below (n = 22) or equal or above (n = 9) 20 IU dL À1 are shown in Table 3 and Table 4 ). Three quarters of the preoperative infusions were performed within 3 h before the procedure. For other infusions, postponement of the procedure up to 14 h after infusion was often due to technical reasons in case of caesarean sections. One 81-year-old patient (UPN 35-02) was treated 13 h before surgery to reduce the thrombosis risk for total hip prosthesis. , and the second was a posttraumatic elbow haemarthrosis in a 7-year-old patient with FXI level of 3 IU dL À1 requiring four injections at 22 IU kg
À1
. The outcome of all surgeries was excellent (93%) or good (7%) (95% CI: 73.5-100.0%). It is noteworthy that there were no excessive bleeds during the operation in six severe FXI-deficient patients who received the lowest preoperative doses (15 U kg À1 or less) for eight surgeries. However, reduced haemoglobin levels required transfusion on the third postoperative day due to a large haematoma of the operative scar in an 81-year-old patient who underwent a right total hip arthroplasty (UPN 35-02) after a single dose of 15 U kg
. RBC units were transfused during surgery on four other occasions due to significant haemoglobin decreases, either the day of the procedure (pancreatic cyst excision (UPN 04-01), hepatectomy (UPN 34-05) and aortic valve replacement (UPN 20-01) or the day after (left total hip arthroplasty, UPN 35-02) ( Table 3 ). Response to HE-MOLEVEN was not documented in two cases because of a concomitant confounding haemorrhagic factor: uterine atony following caesarean section (UPN 36-09) and postpartum haemorrhage leading to the use of concomitant other curative treatments (UPN 36-03) .
FXI recovery could only be evaluated in 12 patients at baseline, as most patients did not have both pre-and postinfusion sampling. Median incremental recovery measured within 2 h post infusion was 2.0 IU dL À1 per U kg À1 (range: 0.7-2.2). The results were comparable between obese and non-obese patients (2.1 IU dL 1 per U kg À1 vs. 1.9 IU dL À1 per U kg
).
Safety
The study follow-up varied between 4 days and 31 months and the median treatment exposure per patient was 2 days (range: 1-22 days). Seven AEs in seven of 44 patients (15.9%) were attributed to HE-MOLEVEN. Five of these AEs, rated as mild or moderate, resolved promptly and spontaneously: vertigo, pain at the injection site, pain in extremity, D-dimer increase.
No biological signs of DIC or clinical symptoms suggesting thrombosis were reported in the obstetrical context. A total of 12 pregnant women received replacement therapy prior to 13 live births and no detectable deleterious effects were observed in the neonates. Two of seven AEs fulfilled the criteria for SAEs. In the first case (UPN 38-03, Table 3 ), acute non-febrile respiratory distress associated with agitation appeared about 15 h after the HEMOLEVEN infusion and 7 h after a neurosurgical procedure, causing the death of the patient. Unfortunately, no autopsy was performed. ), air travel and large fatty tissue around large pack of varicose veins), although no hereditary biological abnormality predisposing to thromboembolism was detected retrospectively using a preoperative frozen plasma. Considering these data, this SAE was rated as a possibly drug related. In the second case (UPN 22-04) , an inhibitor to FXI was diagnosed 3 months after an inguinal hernia surgery. This patient was homozygous for a FXI null mutation (C118X in exon 5). The inhibitor was undetectable 1 year later, but an anamnestic response upper than 500 BU after a new administration for surgery was reported to the pharmacovigilance unit after the end of the study.
Discussion
We report here a large prospective series investigating routine use of a human plasma-derived FXI concentrate in FXI-deficient patients including numerous patients with severe defect. Only case reports with HEMOLEVEN or limited series with BPL concentrate have been published so far [15] [16] [17] [18] [19] . FXI concentrates are of special interest considering their reduced volume compared with FFP and their reduced risk of viral transmission or clinical intolerance [6, 7] . We acknowledge the limitations of this observational study and in particular the lack of homogeneity in the use of HEMOLEVEN and its biological monitoring. Our major aim was to evaluate this concentrate in routine practice after more than 15 years of commercial availability for an orphan disease.
This work confirms previous data regarding the efficacy of HEMOLEVEN obtained from 31 French patients [9] . The recovery here was 2.0 IU dL À1 U kg À1 , which is in accordance with the SmPC. The circumstances of use varied either for preventing haemorrhages in invasive procedures, or more rarely for treating overt bleeding episodes. Expected haemostasis was obtained in 93% of the procedures. Of note, the two patients who achieved only a suboptimal response presented with particular clinical conditions: a GI haemorrhage whose management is not restricted to the use of HEMOLEVEN and a joint bleeding which is not a feature of FXI deficiency. Tranexamic acid was given on 11 occasions concurrently or apart from the FXI concentrate to control mucosal bleeding. There may have been possible unnecessary use of HEMOLEVEN in a significant fraction of our patients, especially in those who were non-severely deficient and had no past history of bleeding after surgical challenges. It is now well established that FXI concentrate infusions are not recommended for dental extractions, and tranexamic acid is the therapy of choice even in severe deficiency [20] . Here, pregnant women who had previously experienced postdelivery bleeding did not develop any haemorrhagic complication under HEMOLEVEN. Kadir et al. reported no significant modifications in FXI:C levels during pregnancy in eight FXI-deficient women [21] . However, prophylactic therapy for vaginal delivery might not be mandatory in FXI-deficient patients. Salomon et al. reported a low frequency of bleeding complications after delivery in severe deficient patients. Of the 62 women who underwent 139 vaginal and 13 caesarean deliveries, 43 (69%) did not develop any postpartum bleeding [22] . Perioperative haemostasis was achieved with doses as low as ≤15 U kg À1 either in severe or in non-severe patients, except in one elderly patient undergoing orthopaedic surgery. Therefore, considering the risk of coagulation overstimulation and thrombosis, our experience does not support the use of higher dosages. We postulate that physiological changes during surgery, for example, platelet activation, could also contribute to haemostasis. Replacement therapy in patients with severe FXI deficiency contributes to normal haemostasis by increasing the thrombin burst.
The coagulation activation following infusion of concentrates in FXI-deficient individuals has been reported using a series of markers: prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin complex (TAT) and fibrinopeptide A [16, 23] . Delayed signs of secondary fibrinolysis (D-dimer and plasmin-antiplasmin complex elevations) were also observed [16] . FXI concentrates have been associated with increased risk of consumptive coagulopathy [8, 13, 14, 16, 23] or thromboembolic events [17] . The sudden presumed pulmonary embolism with fatal outcome immediately after surgery in one patient receiving a dose (21.6 U kg À1 ) below the upper limit of 30 U kg À1 is a matter of concern and underscores the need to reassess the treatment recommendations and the benefit/risk ratio. Multiple environmental thromboembolic risk factors were present in this patient who probably presented an early pulmonary embolism. Unfortunately, in the absence of postmortem investigations, no formal conclusion about the cause of this fatal event can be drawn. Boehlen et al. reported recently a similar thrombotic complication following bariatric surgery in an obese patient (BMI 41.9 kg m
À2
) who received 27 U kg À1 before intervention [25] . These cases were included in a recent update on the risk of thrombosis associated with the FXI concentrate published by Bolton-Maggs et al. [29] . In this review, a total of 12 thromboembolic events with HEMOLEVEN have been reported to LFB from 2002. In the previous French series of 31 patients undergoing 33 procedures with the pure FXI concentrate and evaluated using a questionnaire sent to physicians in 1995, biological DIC was observed in three individuals (one of whom developed venous thrombosis and pulmonary embolism 10 days later) [9] . Of interest, these three patients who received HEMOLEVEN before 1994 were over 60 years old and the first infusion dose exceeded 40 U kg
À1
. These events led to definition of 30 U kg À1 as the recommended upper safety limit. In our series, the dose administered was <30 U kg À1 in 94% of the infusions (134/143). Among 25 patients submitted to 45 haemorrhagic challenges, the BPL FXI concentrate induced serious AEs in three individuals as reported by Collins et al. in 1995: one death of myocardial infarction in a patient with a previous history of cardiovascular disease, a transient ischaemic heart episode and a delayed bilateral pulmonary embolism after a prolonged course of concentrate administration [17] . In this cohort, the dose was double in comparison with that used in our study suggesting a tendency to dose reduction over time. We did not see any thrombotic complication after hip replacement which is considered as a high-risk situation for thromboembolism. Santoro et al. described the successful use of repeated low doses (10-15 U kg
) of HEMOLEVEN, a first dose of 15 U kg À1 12 h before and three doses of 10 U kg À1 every 3 days after hip arthroplasty without any complication [19] . In our study, thromboprophylaxis was used mainly in orthopaedic and abdominal surgery (10 procedures).
We report here a specific high-titre FXI inhibitor that developed after three consecutive infusions in a previously untreated patient. Without reintroduction, the inhibitor was undetectable and these patients should most likely be identified before major surgery. A similar complication was described previously in response to replacement therapy with FFP [24] . In contrast to the aforementioned study, the involved mutation is not described in association with inhibitor formation [26] . This complication is recognized in patients with stop codon mutations and this is another reason for avoiding FXI-containing therapies.
This longitudinal study has greatly improved our policy for the management of FXI-deficient patients in various therapeutic situations. Overall, considering the physiology of FXI [27] and the thrombosis risk associated with either high FXI levels in the normal population [28] or infusion of FXI concentrates in deficient individuals [13, 16, 17, 29] , innovative uses of HEMOLEVEN need to be developed if the replacement therapy with FXI concentrate is essential. First, the traditional dose of 20-30 U kg À1 is probably excessive and 10-15 U kg À1 could suffice in most cases [10, 19] . Second, the timing of injection should be reconsidered in light of the D-dimer kinetics and long half-life of FXI [19] . HEMOLEVEN must be used with caution in patients with significant risk factors for thromboembolism and activated states of coagulation [16, 23, 29] . Screening for early biological signs of DIC is strongly recommended, especially for surgical procedures and in high-risk patients such as obese or elderly patients, and pregnant women. For surgery, thromboprophylaxis must be given according to the local guidelines in both deficient and non-deficient individuals. HEMOLEVEN is a powerful tool for protecting against bleeding; however, the potential risk of thrombosis is a major issue that should not be neglected. Our data argue in favour of low doses to reach recommended FXI levels of 30-40 IU dL
. Based on the recent revised guidelines [29] , the benefit/risk ratio of HEMOLEVEN could be improving. In summary, this FXI concentrate should be used sparingly. The potential haemostatic benefits of use must be weighted and management must be tailored to each individual patient.
